Sorafenib in advanced hepatocellular carcinoma

Cited by (1,037)

Items 901–1,000 of 1,037

1. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer
   Dong-Yu Gao, Ts-Ting Lin, Yun‐Chieh Sung, Ya Chi Liu, Wen‐Hsuan Chiang, Chih-Chun Chang, Jiayu Liu, Yunching Chen · 2015 · Biomaterials
2. Cancer chemotherapy: A critical analysis of its 60 years of history
   Darío Galmarini, Carlos María Galmarini, Felipe C. Galmarini · 2012 · Critical Reviews in Oncology/Hematology
3. MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib
   Paola Stiuso, Nicoletta Potenza, Angela Lombardi, Ida Ferrandino, Antonio Monaco, Silvia Zappavigna, Daniela Vanacore, Nicola Mosca, Filomena Castiello, Stefania Porto et al. · 2015 · Molecular Therapy — Nucleic Acids
4. RNA helicase DEAD box protein 5 regulates Polycomb repressive complex 2/Hox transcript antisense intergenic RNA function in hepatitis B virus infection and hepatocarcinogenesis
   Hao Zhang, Zheng Xing, Saravana Kumar Kailasam Mani, Brigitte Bancel, David Durantel, Fabien Zoulim, Elizabeth J. Tran, Philippe Merle, OURANIA M. ANDRISANI · 2016 · Hepatology
5. BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers
   Jaquelyn Sanchez, Ton Wang, Mark Steven Cohen · 2018 · Drugs
6. Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients
   Atsushi Hiraoka, Takashi Kumada, Kojiro Michitaka, Masatoshi Kudo · 2018 · Liver Cancer
7. Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy
   Anthony Tanoto Tan, Ninghan Yang, Thinesh Lee Krishnamoorthy, Vincent Oei, Alicia Chua, Xinyuan Zhao, Hui Si Tan, Adeline Chia, Nina Le Bert, Diana H. P. Low et al. · 2019 · Gastroenterology
8. M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma
   Ningning Dong, Xiangyi Shi, Suihai Wang, Yanjun Gao, Zhenzhan Kuang, Qian Reuben Xie, Yonglong Li, Huan Deng, Yingsong Wu, Ming Li et al. · 2019 · British Journal of Cancer
9. STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma
   Carol Lee, ST Cheung · 2019 · Cancers
10. Ocular Toxicity of Targeted Therapies
    Renouf, Daniel J., Velazquez-Martin, Juan P., Simpson, Rand, Siu, Lillian L., Bedard, Philippe L. · 2012 · Journal of Clinical Oncology
11. Liquid biopsy in the clinical management of hepatocellular carcinoma
    von Felden, Johann, Garcia-Lezana, Teresa, Schulze, Kornelius, Losic, Bojan, Villanueva, Augusto · 2020 · Gut
12. HCC therapies—lessons learned
    Marcus‐Alexander Wörns, Peter R. Galle · 2014 · Nature Reviews Gastroenterology & Hepatology
13. PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients
    Tao Han, Daimin Xiang, Wen Ce Sun, Na Liu, Huanlin Sun, Wen Wen, Wei-Feng Shen, Ruoyu Wang, Cheng Yeh Chen, Xue Bing Wang et al. · 2015 · Journal of Hepatology
14. Pathogenesis of hepatocellular carcinoma and molecular therapies
    Beatriz Mínguez, Victoria Tovar, Derek Y. Chiang, Augusto Villanueva, Josep Maria Llovet · 2009 · Current Opinion in Gastroenterology
15. Mechanisms of resistance to anti-angiogenesis therapies
    Sandy Giuliano, Gilles Pagès · 2013 · Biochimie
16. Anatomic versus nonanatomic resection in cirrhotic patients with early hepatocellular carcinoma
    Alessandro Cucchetti, Guoliang Qiao, Matteo Cescon, Jun Li, Yong Xia, Giorgio Ercolani, Feng Shen, Antonio Daniele Pinna · 2013 · Surgery
17. Management of Sorafenib-Related Adverse Events: A Clinician’s Perspective
    Marcia S. Brose, Catherine T Frenette, Stephen J. O’Keefe, Stacey Stein · 2014 · Seminars in Oncology
18. New advances in hepatocellular carcinoma
    Sonia Pascual, Iván Herrera, Javier Irurzun · 2016 · World Journal of Hepatology
19. Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study
    Kazuomi Ueshima, Naoshi Nishida, Satoru Hagiwara, Tomoko Aoki, Tomohiro Minami, Hirokazu Chishina, Masahiro Takita, Yasunori Minami, Hiroshi Ida, Mamoru Takenaka et al. · 2019 · Cancers
20. Glypican 3-Targeted Therapy in Hepatocellular Carcinoma
    Takahiro Nishida, Hiroaki Kataoka · 2019 · Cancers
21. Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non–Small-Cell Lung Cancer
    Nasser Khaled Altorki, Maureen E. Lane, THOMAS L BAUER, Paul C. Lee, Michael J. Guarino, Harvey Ira Pass, Enriqueta Felip, Nili Peylan‐Ramu, Alfonso Gúrpide, Frederic W. Grannis et al. · 2010 · Journal of Clinical Oncology
22. Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study
    Michael Bitzer, Marius Horger, Edoardo Giovanni Giannini, Tom M. Ganten, Marcus‐Alexander Wörns, Jens Thomas Siveke, Matthias Dollinger, Guido Gerken, Max Ernst Scheulen, Henning Wege et al. · 2016 · Journal of Hepatology
23. Liver Allograft Failure After Nivolumab Treatment—A Case Report With Systematic Literature Research
    Dimitri Gassmann, Stefan Weiler, Joachim C. Mertens, Cäcilia S. Reiner, Bart Vrugt, Mirjam Nägeli, Joanna Mangana, Beat Müllhaupt, Fabienne Jenni, Benjamin Misselwitz · 2018 · Transplantation Direct
24. 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
    2022 · Korean Journal of Radiology
25. Phase 2 trial of sorafenib in patients with advanced urothelial cancer
    Robert Dreicer, Hailun Li, Mark N. Stein, Robert S. DiPaola, Michael K. Eleff, Bruce J. Roth, George Wilding · 2009 · Cancer
26. Targeting c-Myc as a novel approach for hepatocellular carcinoma
    Che-Pin Lin, Chien-Ru Liu, Chun-Nin Lee, Tze‐Sian Chan, H Eugene Liu · 2010 · World Journal of Hepatology
27. Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis
    Wen‐Lung Ma, Cheng-Lung Hsu, Chun Chieh Yeh, Ming-Heng Wu, Chiung-Kuei Huang, Long-Bin Benjamin Jeng, Yao-Ching Hung, Tze Yi Lin, Shuyuan Yeh, Chawnshang Chang · 2012 · Hepatology
28. The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study
    Maïté Lewin, Lætitia Fartoux, Alexandre Vignaud, Lionel Arrivé, Y. Menu, Olivier Rosmorduc · 2010 · European Radiology
29. Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib
    Aline Houessinon, Catherine François, Chloé Sauzay, Christophe Louandre, Gaëlle Mongélard, Corinne Godin, Sandra Bodeau, Shinichiro Takahashi, Zuzana Saidak, Laurent Gutierrez et al. · 2016 · Molecular Cancer
30. Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions
    Siddharth A. Padia, Robert J. Lewandowski, Guy E. Johnson, Daniel Y. Sze, Thomas J. Ward, Ron Charles Gaba, Mark Otto Baerlocher, Vanessa L. Gates, Ahsun Riaz, Daniel B. Brown et al. · 2016 · Journal of Vascular and Interventional Radiology
31. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma
    J. von Felden, Amanda J. Craig, Teresa Garcia-Lezana, I. Labgaa, Philipp K. Haber, D. D'Avola, Amon Asgharpour, D. Dieterich, A. Bonaccorso, M. Torres-Martín et al. · 2020 · Oncogene
32. Cellular heterogeneity and plasticity in liver cancer
    Lo‐Kong Chan, Yu‐Man Tsui, Daniel Wai‐Hung Ho, Irene Oi‐Lin Ng · 2021 · Seminars in Cancer Biology
33. Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
    Jiayi Wu, Zhenyu Yin, Yannan Bai, Yufeng Chen, Songqiang Zhou, Shuangjia Wang, Jianyin Zhou, Yinan Li, Funan Qiu, Bin Li et al. · 2021 · Journal of Hepatocellular Carcinoma
34. Diffusion MR Imaging for Monitoring of Treatment Response
    Anwar R. Padhani, Dow‐Mu Koh · 2010 · Magnetic Resonance Imaging Clinics of North America
35. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme
    Markus Hermann Moehler, Annett Maderer, Christoph C. Schimanski, Stephan Kanzler, Ulrike Walburga Denzer, Frank Thomas Kolligs, M. Ebert, Andrea Distelrath, Michael Geißler, Jörg Trojan et al. · 2014 · European Journal of Cancer
36. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study
    Robin Kate Kelley, Chris Verslype, Allen Lee Cohn, T.-S. Yang, Wu‐Chou Su, Howard A. Burris, Fadi Braiteh, Nicholas J. Vogelzang, Alexander I. Spira, Paul Foster et al. · 2017 · Annals of Oncology
37. Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells
    Tao Bai, Shuai Wang, Yipu Zhao, Rongtao Zhu, Weijie Wang, Yuling Sun · 2017 · Biochemical and Biophysical Research Communications
38. Lenvatinib
    Koichi Suyama, Hirotaka Iwase · 2018 · Cancer Control
39. Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies
    Po‐Hong Liu, Teh‐Ia Huo, Rebecca Anne Miksad · 2018 · Seminars in Liver Disease
40. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model
    Diana Llópiz, Marta Ruiz, Lorea Villanueva, Tamara Iglesias, Leyre Silva, Josune Egea, Juan José Lasarte, Perrine Pivette, Véronique Trochon-Joseph, Bérangère Vasseur et al. · 2018 · Cancer Immunology Immunotherapy
41. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers
    Lucia Cerrito, Brigida Eleonora Annicchiarico, Roberto Iezzi, Antonio Gasbarrini, Maurizio Pompili, Francesca Romana Ponziani · 2019 · World Journal of Gastroenterology
42. Targeting the RAS oncogene
    Asami Takashima, Douglas V. Faller · 2013 · Expert Opinion on Therapeutic Targets
43. Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models
    Zhaohui Liu, Shusei Hamamichi, Byoung Dae Lee, Dejun Yang, Arpita Ray, Guy A. Caldwell, Kim A. Caldwell, Ted M. Dawson, Wanli Wei Smith, Valina Lynn Dawson · 2011 · Human Molecular Genetics
44. pH-Sensitive Nanoformulated Triptolide as a Targeted Therapeutic Strategy for Hepatocellular Carcinoma
    Daishun Ling, Hongping Xia, Wooram Park, Michael Hackett, Changyeong Song, Kun Na, Kam Man Hui, Taeghwan Hyeon · 2014 · ACS Nano
45. Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST
    María Reig, Anna Darnell, Alejandro Forner, Jordi Rimola, Carmen Ayuso, Jordi Bruix · 2014 · Seminars in Liver Disease
46. Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
    Hanna Kelly Sanoff, YunKyung Chang, Jennifer Leigh Lund, Bert H. O’Neil, Stacie B. Dusetzina · 2016 · The Oncologist
47. Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma
    Masatoshi Kudo · 2018 · Liver Cancer
48. Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities
    Maher Chaar, Jeff Kamta, Sihem Ait‐Oudhia · 2018 · OncoTargets and Therapy
49. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
    Xiufeng Liu, Shukui Qin · 2019 · The Oncologist
50. Systemic Treatment Options in Hepatocellular Carcinoma
    Lorenza Rimassa, Tiziana Pressiani, Philippe Merle · 2019 · Liver Cancer
51. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
    2022 · Journal of Liver Cancer
52. Targeted inhibition of VEGF receptor 2: an update on ramucirumab
    Jeffrey Melson Clarke, Herbert I. Hurwitz · 2013 · Expert Opinion on Biological Therapy
53. Sorafenib Inhibits Hypoxia-Inducible Factor-1α Synthesis: Implications for Antiangiogenic Activity in Hepatocellular Carcinoma
    Liping Liu, Rocky L.K. Ho, George G. Chen, Paul B.S. Lai · 2012 · Clinical Cancer Research
54. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE‐1 study
    Mario Scartozzi, Luca Faloppi, Gianluca Svegliati‐Baroni, Cristian Loretelli, Fabio Piscaglia, Massimo Alberto Iavarone, Pierluigi Toniutto, Giammarco Fava, Samuele De Minicis, Alessandra Mandolesi et al. · 2014 · International Journal of Cancer
55. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008
    Chris Verslype, Eric Van Cutsem, Mario A. Dicato, Nadir Arber, Jordan D. Berlin, David Cunningham, Aimery de Gramont, Eduardo Díaz‐Rubio, Michel Pierre Ducreux, Thomas Gruenberger et al. · 2009 · Annals of Oncology
56. Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung Cancer
    Emer O. Hanrahan, Heather Yan Lin, Edward S. Kim, Shaoyu Yan, D. Z. Du, Kathryn S. McKee, Hai Thanh Tran, J. Jack Lee, Anderson Joseph Ryan, Peter B. Langmuir et al. · 2009 · Journal of Clinical Oncology
57. Blocking the CCL2–CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model
    Kun‐Yu Teng, Jianfeng Han, Xiaoli Zhang, Shu‐Hao Hsu, Shun He, Nissar Ahmad Wani, Juan Martin Barajas, Linda A. Snyder, Wendy L. Frankel, Michael A. Caligiuri et al. · 2016 · Molecular Cancer Therapeutics
58. Targeted Therapy in Thyroid Cancer: State of the Art
    Laura Valerio, Letizia Pieruzzi, Carlotta Giani, Laura Agate, Valeria Bottici, Loredana Lorusso, Virginia Cappagli, Luciana Puleo, Antonio Matrone, David Viola et al. · 2017 · Clinical Oncology
59. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma
    Tan Boon Toh, Jhin Jieh Lim, Lissa Hooi, Masturah Bte Mohd Abdul Rashid, Edward Kai‐Hua Chow · 2019 · Journal of Hepatology
60. Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma
    Arndt Vogel, Anna Lena Saborowski · 2019 · Cancer Treatment Reviews
61. STAT3: A Target to Enhance Antitumor Immune Response
    Heehyoung Lee, Sumanta Kumar Pal, Karen L. Reckamp, Robert A. Figlin, Hua Yu · 2010 · Current topics in microbiology and immunology
62. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors
    Pooja Ghatalia, Charity Johanna Morgan, Youjin Je, Paul Linh Nguyen, Quoc‐Dien Trinh, Toni K. Choueiri, Guru Sonpavde · 2014 · Critical Reviews in Oncology/Hematology
63. Overview of Parametric Survival Analysis for Health-Economic Applications
    K. Jack Ishak, Noémi Kreif, Ágnes Benedict, Noemi Muszbek · 2013 · PharmacoEconomics
64. HEPATOCELLULAR CARCINOMA: DIAGNOSIS AND OPERATIVE MANAGEMENT
    Márcio F. Chedid, Cleber Dario Pinto Kruel, Marcelo Alves Pinto, Tomáz de Jesus Maria Grezzana Filho, Ian Leipnitz, Cleber Dario Pinto Kruel, Leandro Armani Scaffaro, Aljamir Duarte Chedid · 2017 · ABCD Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
65. Thermosensitive hydrogels for sustained-release of sorafenib and selenium nanoparticles for localized synergistic chemoradiotherapy
    Lan Zheng, Chang'e Li, Xiaoting Huang, Xueran Lin, Weiqiang Lin, Fang Yang, Tianfeng Chen · 2019 · Biomaterials
66. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
    Markus Hermann Moehler, Jeong Heo, H.C. Lee, Won Young Tak, Yee Chao, Seung Woon Paik, Hyung Joon Yim, Kwan Soo Byun, Ari David Baron, Guy Ungerechts et al. · 2019 · OncoImmunology
67. Vessel co-option and resistance to anti-angiogenic therapy
    Elizabeth A. Kuczynski, Andrew R. Reynolds · 2019 · Angiogenesis
68. Clinical decision making and research in hepatocellular carcinoma: Pivotal role of imaging techniques
    Jordi Bruix, María Reig, Jordi Rimola, Alejandro Forner, Marta Burrel, Ramón Vilana, Carmen Ayuso · 2010 · Hepatology
69. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
    Chih‐Hung Hsu, T-S Yang, Chiun Hsu, Han Chong Toh, Richard J. Epstein, L-T Hsiao, P-J Chen, Z-Z Lin, T-Y Chao, A-L Cheng · 2010 · British Journal of Cancer
70. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma
    David A. Reardon, James J. Vredenburgh, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, John Howard Sampson, Jennifer E. Marcello, James E. Herndon, Roger E. McLendon, Dorothea Janney et al. · 2010 · Journal of Neuro-Oncology
71. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29).
    D. Koeberle, J. Dufour, G. Demeter, Q. Li, K. Ribi, P. Samaras, P. Saletti, A. Roth, D. Horber, M. Buehlmann et al. · 2016 · Annals of Oncology
72. Diagnosis and treatment of hepatocellular carcinoma: An update
    Javier Tejeda-Maldonado · 2015 · World Journal of Hepatology
73. Systemic treatment of HCC in special populations
    Lorenza Rimassa, Nicola Personeni, Carolin Czauderna, Friedrich Foerster, Peter Robert Galle · 2020 · Journal of Hepatology
74. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population
    Andrea Casadei Gardini, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa et al. · 2022 · European Journal of Cancer
75. Mitochondrial TSPO Promotes Hepatocellular Carcinoma Progression through Ferroptosis Inhibition and Immune Evasion
    Deguo Zhang, Da Man, Jiahua Lu, Yifan Jiang, Bo Ding, Rong Su, Rongliang Tong, Junru Chen, Beng Yang, Shusen Zheng et al. · 2023 · Advanced Science
76. Efficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma
    Valérie Boige, David Malka, Abderrahmane Bourredjem, Clarisse Dromain, Charlotte Baey, Nathalie Jacques, Jean‐Pierre Pignon, Nadège Vimond, N. Bouvet-Forteau, Thierry de Baère et al. · 2012 · The Oncologist
77. Elevated hepatocyte growth factor expression as an autocrine c‐Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells
    Zeynep Fırtına Karagonlar, Doğukan Koç, Evin İşcan, Esra Erdal, Neşe Atabey · 2016 · Cancer Science
78. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis
    Jong Hwan Choi, Woo Jin Chung, Si Hyun Bae, Do Seon Song, Myeong Jun Song, Young Seok Kim, Hyung Joon Yim, Young Kul Jung, Sang Jun Suh, Jun Yong Park et al. · 2018 · Cancer Chemotherapy and Pharmacology
79. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti–PD‐1 therapy
    Sirish Dharmapuri, Umut Özbek, Jung‐Yi Lin, Max W. Sung, Myron Schwartz, Andrea D. Branch, Celina Ang · 2020 · Cancer Medicine
80. Nanoparticle Delivery of MnO2 and Antiangiogenic Therapy to Overcome Hypoxia-Driven Tumor Escape and Suppress Hepatocellular Carcinoma
    Chih-Chun Chang, Trinh Kieu Dinh, Yi-An Lee, Fu‐Nien Wang, Yun‐Chieh Sung, Pei-Lun Yu, Shao‐Chieh Chiu, Yu‐Chuan Shih, Chengyun Wu, Yi-Da Huang et al. · 2020 · ACS Applied Materials & Interfaces
81. Dual Targeting of Histone Methyltransferase G9a and DNA‐Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma
    Bárcena‐Varela, Marina, Caruso, Stefano, Llerena, Susana, Álvarez‐Sola, Gloria, Uriarte, Iker, Latasa, M. Ujue, Urtasun, Raquel, Rebouissou, Sandra, Alvarez, Laura, Jimenez, Maddalen et al. · 2019 · Hepatology
82. Phase 2 Study of Combined Sorafenib and Radiation Therapy in Patients With Advanced Hepatocellular Carcinoma
    Shang-Wen Chen, Li-Ching Lin, Yu-Cheng Kuo, Ji‐An Liang, Chia‐Chun Kuo, Jeng-Fong Chiou · 2014 · International Journal of Radiation Oncology*Biology*Physics
83. Staging systems of hepatocellular carcinoma: A review of literature
    Marcello Fabio Maida · 2014 · World Journal of Gastroenterology
84. Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib
    Massimo Alberto Iavarone, Giuseppe Cabibbo, Marco Biolato, Cristina Della Corte, Marcello Fabio Maida, Marco Barbàra, Michele Basso, Sara Vavassori, Antonio Craxı̀, Antonio Grieco et al. · 2015 · Hepatology
85. Fibroblast growth factor receptors, developmental corruption and malignant disease.
    F. Kelleher, H. O'Sullivan, E. Smyth, R. McDermott, A. Viterbo · 2013 · Carcinogenesis
86. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models
    Iris Martinez-Quetglas, Roser Pinyol, Daniel Dauch, Sara Torrecilla, Victoria Tovar, Agrin Moeini, Clara Alsinet, Anna Portela, Leonardo Rodríguez‐Carunchio, Manel Solé et al. · 2016 · Gastroenterology
87. Immune Checkpoint Inhibitors in the Treatment of HCC
    Clelia Donisi, Marco Puzzoni, Pina Ziranu, Eleonora Lai, Stefano Mariani, Giorgio Saba, Valentino Impera, Marco Dubois, Mara Persano, Marco Migliari et al. · 2021 · Frontiers in Oncology
88. Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape
    Emily Noelle Kinsey, Hannah M. Lee · 2024 · Cancers
89. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma
    Hung The Huynh, Van Chanh Ngo, Heng Nung Koong, Donald Y. H. Poon, Su Pin Choo, Choon Hua Thng, Pierce K. H. Chow, Hock Soo Ong, Alexander Yaw Fui Chung, Khee Chee Soo · 2009 · Journal of Cellular and Molecular Medicine
90. Prevention of recurrence after resection of hepatocellular carcinoma: A daunting challenge
    Ronnie T. P. Poon · 2011 · Hepatology
91. Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge
    Martin‐Walter Welker, Wolf O. Bechstein, Stefan Zeuzem, Joerg Trojan · 2012 · Transplant International
92. Recent advances in the treatment of hepatocellular carcinoma
    Amit G. Singal, Jorge A. Marrero · 2010 · Current Opinion in Gastroenterology
93. Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma
    Hsin‐Jung Lee, Yung‐Ming Jeng, Yu‐Ling Chen, Ling Chung, Ray‐Hwang Yuan · 2013 · Carcinogenesis
94. Long-Term Results of a Randomized, Observation-Controlled, Phase III Trial of Adjuvant Interferon Alfa-2b in Hepatocellular Carcinoma After Curative Resection
    Li‐Tzong Chen, Miin‐Fu Chen, Lung-An Li, Po‐Huang Lee, Long‐Bin Jeng, Deng‐Yn Lin, Cheng-Chung Wu, King‐Tong Mok, Chao‐Long Chen, Wei‐Chen Lee et al. · 2011 · Annals of Surgery
95. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma
    Shuai Lü, Yao Yao, Guolong Xu, Chao Hui ZHOU, Yuan Zhang, Jie Sun, Runqiu Jiang, Qing Shao, Yun Chen · 2018 · Cell Death and Disease
96. New insights on sorafenib resistance in liver cancer with correlation of individualized therapy
    Cheng Zhang, Jiang Wei-Qi, Ding Jin · 2020 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
97. Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients
    Daan C.H. van Dorst, Stephen J.H. Dobbin, Karla Bianca Neves, Joerg Herrmann, Sandra M. Herrmann, Jorie Versmissen, Ron H.J. Mathijssen, A.H. Jan Danser, Ninian N. Lang · 2021 · Circulation Research
98. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
    Chih‐Hung Hsu, Yiwei Shen, Zhong-Zhe Lin, Pei-Jer Chen, Yu-Yun Shao, Yea-Hui Ding, Chiun Hsu, Ann-Lii Cheng · 2010 · Journal of Hepatology
99. Single-Center Phase II Trial of Transarterial Chemoembolization With Drug-Eluting Beads for Patients With Unresectable Hepatocellular Carcinoma
    Diane K. Reyes, Josephina Anna Vossen, Ihab R. Kamel, Nilofer Saba Azad, Tamara A. Wahlin, Michael S Torbenson, Michael A. Choti, Jean-François H. Geschwind · 2009 · The Cancer Journal
100. The Role of Sinusoidal Endothelial Cells in the Axis of Inflammation and Cancer Within the Liver
     Wilkinson, Alex L., Qurashi, Maria, Shetty, Shishir · 2020 · Frontiers in Physiology